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xplorers have traditionally set out from familiar ports toward the
unknown, creating maps of where they have been for others to follow.
With time, these rough drawings are refined by those who come in their
wake so that coastlines are charted, mountains measured, and rivers
delineated to the mile. Today, scientists are grappling with a new map—that
of the human genome—but unlike the one you can barely fold in your car,
this map describes a landscape that remains almost a complete mystery: the
3.2 billion letters of DNA that code for the creation of a human being. The
human genome is the total amount of DNA spooled into a set of 23
chromosomes found in the nucleus of every human cell. It’s formed when the
chromosomes of the male’s sperm fuse with those of the female’s egg to form
a single-celled embryo, and it contains the genetic “instructions” that allow
Focus •  Charting the Map of Lifethe embryo to grow into a fully formed
person.
When scientists announced they had
mapped a rough draft of the human
genome—identified 85–90% of the
ordered sequence of DNA on each chromo-
some—the event was lauded around the
world as the greatest scientific achievement
since the Apollo 11 moon landing. Some
scientists called the accomplishment noth-
ing less than the beginning of a true under-
standing of biology. At a 27 June 2000
White House ceremony featuring the heads
of the two teams responsible for the feat—
J. Craig Venter, president and chief
scientific officer of the Rockville,
Maryland–based Celera Genomics, a pri-
vately funded biotechnology company, and
Francis S. Collins, director of the publicly
funded National Human Genome Research
Institute—President Clinton said, “Today
we are learning the language in which God
created life.” 
The map of the human genome points
to a vast uncharted territory, much of it a
wasteland. Only 3–5% of the genome—
corresponding to between 30,000 and
100,000 functional genes—is thought to be
biologically functional. The remainder is
so-called junk DNA that may someday be
shown to have biologic merit, but that for
now is largely seen as filler that remains in
the genome for unknown reasons. Scientists
expect that mapping the genome will lead
to a host of innovations in biology and
research. For example, DNA microarrays,
devices that analyze the level of expression
of thou-
sands of
genes at a time, could
be used to accurately diag-
nose cancer and infectious
disease subtypes and to predict
clinical outcomes. Scientists will also
use the genome to look at the interactions
of the environment, genetic makeup, and
toxic exposures, including the ability of cer-
tain genes to detoxify the body and pro-
mote disease resistance. 
The genome will provide tremendous
resources for understanding human diversi-
ty and evolution. All humans on the planet
are roughly 99.9% genomically identical,
not surprising considering a common
ancestry thought to date back 150,000
years to a tiny band of people in Africa.
Within the remaining 0.1% of the genome
are the 3 million letters of DNA that gov-
ern our physical differences. Many portions
of the human genome, particularly those
coding for metabolic processes, are identical
to those of other species. Comparative
genomics studies will provide insight into
how metabolic and other physiologic sys-
tems evolved in different species. 
But despite the great potential of
genomics, scientists caution that public
expectations need to be tempered with real-
ity. Decrying what she calls the “media
inflation of genetic technology,” Lily Kay,
an associate of the museum of comparative
zoology at Harvard University in
Cambridge and author of Who Wrote the
Book of Life? A History of the Genetic Code,
says, “We are bombard-
ed daily by media
reports of the genetic rev-
olution. And the usual
approach is to absorb uncriti-
cally these scientific forecasts as
fait accompli.” The fact is, she says,
people are as much a product of their envi-
ronment as they are of their genes. And to
suggest that genetics is the sole determinant
that defines us as individuals, writes Eric
Lander, director of the Whitehead Center
for Genome Research in Cambridge, in a
12 June 2000 editorial in The New York
Times, “stretches the science far beyond the
data.” 
The Nuts and Bolts
Mapping the human genome is the most
recent event in a genetic time line dating
back to Gregor Mendel, who discovered the
basic principles of heredity in the mid-
1800s. Mendel introduced the concept of
the gene as a unit of information through
which hereditary information is passed
from one generation to the next. Later, the
concept became less abstract with the dis-
covery that genes are made of the substance
DNA. The three-dimensional structure of
DNA and its method of replication was dis-
covered by James Watson, an American
postdoctoral fellow, and British graduate
student Francis Crick at Cambridge
University in England. In their classic paper
titled “Molecular Structure of Nucleic
Acids. A Structure for Deoxyribose Nucleic
Acid,” published in Nature in 1953, the
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form of the molecule, shaped like a twisted
ladder, in which each rung is made up of
four nucleotides: adenine, thymine, cyto-
sine, and guanine (typically abbreviated as
A, T, C, and G). The nucleotides are
arranged in a series of base pairs, in which A
bonds with T, and C with G. In the years
that followed, researchers discovered that
genes code for amino acid sequences, which
themselves comprise the proteins that make
life possible. 
A genome map is essentially a represen-
tation of where genes are located on the
chromosome. At the coarsest level of resolu-
tion are genetic linkage maps, which
describe gene locations based on their pat-
terns of inheritance, for instance as observed
in mating experiments with Drosophila
melanogaster (fruit fly). The first such map
was developed in 1913 by Alfred Sturtevant
while he was an undergraduate in zoology
at New York’s Columbia University.
Working with embryologist Thomas Hunt
Morgan in the legendary “fly room” at
Columbia, Sturtevant arranged the ordered
sequence of genes for eye color, wing shape,
body size, and other characteristics based on
their appearance in consecutive generations
of Drosophila. Morgan himself was the first
to associate a specific gene with a specific
chromosome; again experimenting with
fruit flies, Morgan found that the mutant
gene for white eyes (most fruit flies have red
eyes) is found only in male progeny and is
located exclusively on the X chromosome—
a discovery for which he won the Nobel
Prize for Medicine in 1933. 
Gene mapping (and indeed, the whole
field of molecular biology) hit its stride in
the late 1960s with the discovery that
restriction enzymes could be used to cut
DNA into specific sequences. In nature,
restriction enzymes protect bacteria by slic-
ing up invading viral DNA. But in the lab-
oratory, they can be used as molecular “scis-
sors” that recognize a highly specific DNA
sequence, or type of sequence, and then cut
the DNA at the same site in the sequence.
Over 3,000 restriction enzymes have been
identified to date, affording scientists great
specificity when chopping DNA into isolat-
ed fragments. The fragments can be cloned
(usually in bacteria) or duplicated using a
variety of biochemical techniques to provide
the unlimited genetic material needed for
experimental studies. 
These techniques have been used to
generate higher-resolution physical maps
that describe the biochemical structure of
DNA and the ordered sequence of the
genes themselves. By the early 1990s, scien-
tists were constructing physical maps of
model organisms using a procedure called
map-based sequencing. The process
involves cutting DNA into fragments of
about 200,000 base pairs called bacterial
artificial chromosomes (BACs), taking note
to record the position of the BACs on the
genome, cloning the BACs in bacteria
(such as Escherichia coli), determining the
sequence of the base pairs, and then
reassembling the BACs in their original
order using a computer. 
Map-based sequencing is the technique
of choice for the Human Genome Project
(HGP), a consortium of research centers
funded by the National Institutes of
Health, the U.S. Department of Energy,
and the Wellcome Trust, a medical philan-
thropy based in London. The HGP was
formed in 1990, with the goal of mapping
the human genome by 2005, a date short-
ened by five years by politics, competition,
and a variety of technical innovations. In
addition to mapping the human genome,
the project aims to store the information in
databases, address the ethical, legal, and
social issues raised by the project, and devel-
op tools for data analysis and better
sequencing technologies.
Scientists had still not completed a
genome map for any organism by 1994,
the year Venter and Nobel Prize–winning
molecular biologist Hamilton O. Smith
proposed speeding up the process with an
alternative method they called whole-
genome shotgun sequencing. In contrast to
the HGP’s method, in which the order of
the BACs is known before they are each
sequenced individually and then reassem-
bled, the shotgun method involves cutting
the DNA into small, random, overlapping
pieces that are then sequenced and reassem-
bled using a computer that compares all
the pieces and matches the overlaps, thus
assembling the whole genome. In 1995,
with this technique, Venter and Smith
mapped the genome of the disease-causing
bacterium Haemophilus influenzae—the
first completed genome of any single
organism. 
The period from 1995 to 2000 gave rise
to a stunning series of technologic advance-
ments, including computer automation and
robotics, that accelerated the rate of genome
mapping. At the forefront was a machine
called the ABI Prism 3700 DNA Analyzer,
introduced in 1998 by the Perkin-Elmer
Corporation. This machine is involved in
the last step of the sequencing pipeline. Its
job is to separate fluorescently labeled DNA
fragments by size to determine the sequence
of nucleotide bases found on a strand of
DNA. Now used by major DNA sequenc-
ing laboratories around the world, the
Prism 3700 increased the rate of genome
sequencing by approximately 20-fold. 
The equipment used by both Celera
and the HGP to draft the map of the
human genome was virtually identical. The
only difference between the two organiza-
tions was their basic methodology: the
HGP used map-based sequencing while
Celera used shotgun sequencing. The physi-
cal map they produced, the “language in
which God created life,” is an eye-numbing
series of As, Ts, Cs, and Gs stretching into
the billions. 
Scientists acknowledge that much work
on the human genome remains to be done.
Since announcing the completion of the
rough draft in June, Celera has moved on to
other more lucrative pursuits befitting a
biotechnology company, such as identifying
and patenting gene sequences. Meanwhile,
the HGP advances toward a final map,
expected to be completed by 2003. At the
present time, the BACs covering the two
smallest chromosomes, numbers 21 and 22,
are essentially complete. Chromosome 22 is
particularly noteworthy: it’s packed with
over 545 known genes (at least 300 more
are suspected) ranging in size from 1,000 to
583,000 bases of DNA. Gene variations on
chromosome 22 are thought to be associat-
ed with at least 27 human disorders includ-
ing brain cancers, schizophrenia, and multi-
ple birth defects. Other BACs on other
chromosomes are still in various states of
disassembly, and there are still significant
gaps to be filled. Nevertheless, the working
draft is considered to be of great value for
researchers looking for genes, and it repre-
sents a major accomplishment. Says Collins,
“The completion of the human genome
sequence will have a profound effect on
understanding genetic contributions to
human disease and the development of
strategies for minimizing and preventing
disease altogether.”
Gene–Environment Interactions
One of the most exciting applications for
genomics is in the area of gene–environ-
ment interactions. Now light-years beyond
the theories of evil spirits and “bad blood”
espoused by our ancestors, modern science
views illness as the outcome of three related
factors: genetics, environmental exposures,
and aging. Like death and taxes, aging is a
certainty. But within the complex interplay
of genes and the environment lies a range of
potential targets for disease prevention and
treatment—particularly for cancer, pul-
monary diseases, neurodegenerative disor-
ders, developmental disorders, birth defects,
reproductive function, and autoimmune
diseases, all of which have been shown to be
influenced by environmental agents. In fact,
in a paper published in the 13 July 2000
issue of the New England Journal of
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Karolinska Institute in Stockholm, Sweden,
and colleagues state, “Inherited genetic fac-
tors make a minor contribution to suscepti-
bility to most types of [cancers]. This find-
ing indicates that the environment has the
principal role in causing sporadic cancer.”
One group spearheading the effort to
elucidate gene–environment interactions is
the Environmental Genome Project (EGP),
headquartered at the NIEHS. Maynard
Olson, director of the University of
Washington Genome Center in Seattle,
where much EGP research is conducted,
describes gene mapping as an “extremely
powerful tool for furthering investigations
into human biology and its interactions
with the environment.” Many of the
enzymes and proteins involved in toxicity
have already been identified in classical cell
biology studies, he says. What genomic
information allows researchers to do is
build on this knowledge by identifying how
many types of these proteins are expressed,
and in what specific tissues they are found. 
The mission of the EGP is to identify
genes already mapped by other programs
(the organization is continually soliciting
candidate genes), and then to resequence
the genes in an exhaustive search for the
variations that augment resistance or sus-
ceptibility to environmental exposures.
Most variants of interest are called single
nucleotide polymorphisms, or SNPs, which
are genes whose ordered DNA sequence is
mixed up in ways that alter protein expres-
sion. If these proteins are involved in
metabolizing or detoxifying chemical
agents, it’s likely that exposure will cause
greater harm. For example, a protein called
p53 participates in cell signaling processes
related to DNA repair, which is important
because DNA is continually bombarded by
carcinogens from inside and outside the
body. If p53 detects chromosomal damage,
it signals the cell to stop DNA synthesis or
even undergo cell death. A person with a
genetically inherited mutation that alters
the function of the p53 gene may be highly
susceptible to cancer. Not surprisingly, the
EGP has focused its initial efforts largely on
finding SNPs among genes that, like p53,
participate in DNA repair. Other processes
of interest include cell cycle control, xeno-
biotic metabolism, and immune and
inflammatory reactions. 
The most recent addition to environ-
mental genomics at the NIEHS is a newly
formed National Center for Toxico-
genomics, announced in December 2000
[see NIEHS News, p. A22]. Jose Velazquez,
a program administrator for the NIEHS
Division of Extramural Research and
Training, says the center will complement
the activities of the EGP by investigating
patterns of gene expression and protein
function in response to chemicals. “It’s not
enough just to understand the expression of
the gene,” he says. “You also have to under-
stand the function of the protein.” The
problem is that protein function—particu-
larly in the context of environmental expo-
sure—is extremely difficult to characterize.
The way the genome reacts to chemicals is
highly dependent on timing and dose.
Either of these parameters can exert a major
influence on gene expression. Furthermore,
chemicals trigger biochemical cascades with-
in cells in which some proteins are turned
off, others are turned on, and some aren’t
affected at all. It’s really more a question of
genome expression than gene expression.
And indeed, many genomic scientists say
the key to the future of genomics is actually
found in functional genomics, or pro-
teomics, which seeks to understand the
global activity of proteins in a cell at any
given time. Understanding how all the
pieces fit together is as much a computa-
tional challenge as it is a biochemical mys-
tery. For this reason, the center has also pro-
posed the improvement of mathematical
paradigms for the study of protein function
as a major agenda item for the future.
The EGP’s ultimate goal is to sponsor
and support epidemiologic studies of
gene–environment interactions, both at the
NIEHS and by outside researchers funded
through the institute’s extramural grants
program. Empowered by databases with
useful information about genes and gene
functions, researchers in the genomic era
will be able to more clearly determine how
specific populations respond to their envi-
ronment. The activities now under way at
the EGP constitute a critical step in that
direction. 
Comparative Genomics
Although the public’s attention has been
captured by human genomics, mapping
and studying the genomes of other organ-
isms—or comparative genomics—is also
important. Jonathan King, a professor of
molecular biology at the Massachusetts
Institute of Technology in Cambridge and
a board member of the Council for
Responsible Genetics, says, “Most genes
evolved long ago, and there is enormous
homology for essential functions like
metabolism.” Therefore, he says, the amino
acid sequences of many proteins are identi-
cal throughout all the higher species, a phe-
nomenon known as genetic conservation.
Comparative genomics is generally under-
taken for two reasons: to provide road maps
that help researchers locate genes for inher-
ited characteristics and behavior in humans
and other creatures, and to advance the
study of genomic evolution. As the maps
become available, blocks of human DNA
will be compared to other species to under-
stand not only sequencing gaps but also
genetic conservation. To date, physical
maps of yeast, the soil worm Caenorhabditis
elegans, and the fruit fly (in addition to
numerous bacteria and viruses) have been
completed. Scientists are also mapping the
genomes of the mouse, rat, cat, dog, pig,
cow, goat, zebrafish, rainbow trout, tilapia
fish, medaka fish, rabbit, chicken, sheep,
and horse. 
Researchers at the Laboratory of
Genomic Diversity (LGD) at the National
Cancer Institute’s Frederick Cancer
Research and Development Center in
Frederick, Maryland, are mapping the cat
genome, which apparently shares more
order homology (meaning similar order of
genes on the chromosome) with the human
than any other nonprimate species that has
been studied. According to William
Murphy, a geneticist with the LGD, this
means that genomes of both cats and
humans have changed relatively little dur-
ing the 90 million years since mammals
diverged from their parent ancestor.
Comparing the genome to a deck of cards,
he says the genes of other laboratory species
including mice, rats, and dogs have been
substantially reshuffled over time, making
them more challenging than the cat for
studying genomic evolutionary history. 
Comparative genomics is also useful for
identifying models of human hereditary dis-
ease. There are a multitude of genetic dis-
eases that show up in humans and other
animals. Cats, for example, carry genes for
hemophilia, polycystic kidney disease, and
hypertrophic cardiomyopathy. According to
an article by Stephen J. O’Brien and col-
leagues from the LGD published in the 15
October 1999 issue of Science, nearly every
human gene has a mouse homologue, mak-
ing this traditional laboratory animal highly
amenable to the study of genetic illnesses.
Studies in mice have already identified
mutated genes for multiple disorders that
are also present in humans. In the best
known example, a mutated gene involved in
metabolism is present in both overweight
mice and morbidly obese humans.
Similarly, comparative mapping studies of
hypertension in rats have uncovered candi-
date genes for the same disease in humans.
Within the year, scientists with the HGP
expect to complete working drafts of the
mouse and rat genomes, which will expand
the potential for comparative inference
relating to human health. As this occurs, sci-
entists will use rodent models, and those of
other species as well, to identify candidate
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tions in humans and to
define their interactions with
other genes in the context of
mutation, environmental
exposure, infectious disease,
sex, aging, and more.
The Myth of Determinism
Ironically, even as gene–environ-
ment interactions grow in scien-
tific prominence, scientists worry
that the recent media hype is help-
ing to resurrect an outdated theory
of “genetic determinism,” which
suggests that individual phenotypes
are governed wholly by genetic make-
up. The danger, they say, is that people
will take a fatalistic attitude toward dis-
ease and discount the effects of environ-
ment and lifestyle. David Page, chair of the
Whitehead Task Force on Genetics and
Public Policy and a professor of biology at
the Massachusetts Institute of Technology,
attributes the problem to a tendency
among scientists to simplify genomics for
the press, which have adopted “Gene X
Causes Disease Y” as their standard head-
line. Without efforts to dispel some of the
fuzziness surrounding genetic mechanisms,
he says, the public will believe the truth is
as simple as the headlines would suggest. 
And just as the genome isn’t determin-
istic in the context of the entire organism,
neither is it deterministic with respect to
the structure of individual proteins.
Knowledge of the genome makes it possi-
ble to describe a protein’s amino acid
sequence, but not to predict its three-
dimensional shape. A host of internal fac-
tors within the cell contribute to protein
“folding,” which governs the protein’s
receptor chemistry and therefore all of its
functionality. This is a major problem for
biotechnology and pharmaceutical compa-
nies hoping to use genomics to create new
classes of drugs—a fact that is rarely appre-
ciated by the public. “This is why gene-
based biotechnology is in trouble,” says
Kay. “Gene-based biotechnology lost $5
billion last year. One hundred seventy-six
drugs were proposed; one was approved,
and the others faltered in the second stage
of clinical trials.”
Ultimately, some suggest, genomics will
be more useful as a research and diagnostic
tool than as an agent that lifts medical treat-
ment to new heights. However, efforts to
use genomics for these purposes are increas-
ingly hamstrung by a new application for
the law in biology: gene patents and intel-
lectual property protection for gene prod-
ucts [see Spheres of Influence, p. A30].
Private-sector companies are increasingly
patenting gene sequences, cell lines, genetically
modified organisms, and even natural
species—a practice that has angered many
prominent scientists. Leveling sharp criticism
at what he calls a “radical extension of patent
law,” King says, “Genes are the products of
millions of years of evolution and are in the
deepest sense products of nature. They are not
the inventions of individuals, corporations, or
institutions.” King predicts that gene patents
will retard research because investigators won’t
share information for fear of undermining the
ability to file patents later, and will impede
health care delivery because providers will need
to pay licensing fees to use gene products. In
addition, he says, such patents provide a legal
mechanism for companies to charge excessive
sums for genetic screening (in the event they
own the patent to the gene sequences of inter-
est to the patient) and even more for gene
therapy (in the event the screen shows the
patient’s own gene is defective). 
But, illustrating the contentious nature of
the debate, these concerns were rejected by
Philip Reilly, the chairman of the board and
chief executive officer of Interleukin
Genetics, a biotechnology company located
in Waltham, Massachusetts. Reilly says that
without legal protection for intellectual prop-
erty, the $20 billion in research dollars spent
annually by biotechnology and pharmaceuti-
cal companies would dry up overnight. “I’m
the CEO of a very small biotech company,”
he says, “and I have never seen a more
Darwinian process than trying to bring a
biotech product forward. The vast majority
of these companies fail, and the return on
investment is very low.” He also charges that
it is false to assume that biotechnology com-
panies are looking to establish a “captive pop-
ulation for gene therapy.” Responding to
negative publicity following the September
1999 death of 18-year-old Jesse Gelsinger,
who died following experimental gene thera-
py for a rare metabolic disorder, he says,
“Venture capital companies are running
scared from gene therapy.”
And so, even as genomics promises to
play a vital role in the future of biologic
research, the overriding question facing soci-
ety is how to use the information in ways that
benefit the common good. Clearly, the
answers to these questions remain unknown.
What seems apparent is that genomics must
be placed in the context of the whole human
experience, including the environment in
which we live. “Poverty is the main source of
disease in the world,” says Olson. “It’s not
genetic variation [that degrades public health]
as much as it is economic variation. And we
shouldn’t forget that.” 
Charles W. Schmidt
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